DUX4 Polypeptide Immunosuppression for Autoimmune Pathway Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional immunosuppressants used to treat autoimmune and inflammatory diseases non-specifically suppress T cells, leading to severe infections and lethal consequences, while the promise of universal donor stem cells is hindered by immune rejection.
Innovation Solution
The use of DUX4 polypeptides and nucleic acids to selectively inhibit immune pathways, such as IFIH1, RIGI, and CGAS, reducing the immune response without affecting non-pathogenic T cells, and the generation of universal donor stem cells to overcome graft versus host rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional immunosuppressants are used to treat autoimmune diseases, then the immune response is suppressed, but non-pathogenic T cells are also affected leading to severe infections
Solution Approach 1:
The patent segments the immune response into pathogenic and non-pathogenic components by using DUX4 polypeptides that specifically target autoimmune pathways (IFIH1, RIGI, CGAS) while preserving normal T cell function. This selective inhibition divides the broad immunosuppression effect into targeted action against disease-causing immune responses only.
Solution Approach 2:
The invention applies local quality by making the immunosuppressive effect specific to certain immune pathways involved in autoimmunity rather than globally suppressing all immune functions. The DUX4 polypeptide exhibits different effects on different immune pathways - inhibiting type I interferon signaling while maintaining normal T cell responsiveness to pathogens.
2Adaptability or versatility
If universal donor stem cells are used for transplantation, then graft availability increases, but immune rejection by graft versus host occurs
Solution Approach 1:
The patent uses DUX4 polypeptides as an intermediary substance that mediates between the transplanted cells and the host immune system. The polypeptide suppresses the host's immune response to the graft without requiring the graft to be immunologically matched to the host, thereby enabling universal donor compatibility.
Solution Approach 2:
The invention applies preliminary anti-action by administering DUX4 polypeptides before or at the time of transplantation to pre-suppress the host immune system's ability to reject the graft. This preemptive immunosuppression prevents graft versus host disease from developing, allowing universal donor cells to engraft successfully.
Data Source
AI summary
The current disclosure provides novel methods and compositions to suppress immunity and are useful for treating autoimmune and inflammatory conditions, and in some circumstances, cancers. Accordingly, aspects of the disclosure relate to a method for treating an inflammatory, autoimmune, autoinflammatory or cancer disease or condition in a subject comprising administering a DUX4 polypeptide or nucleic acid encoding a DUX4 polypeptide to the subject. Further aspects relate to a method for treating a tissue transplant subject, the method comprising administering a DUX4 polypeptide or nucleic acid encoding a DUX4 polypeptide to the subject. The present inventions also relate to universal donor stem cells that overcome immune rejection in cell-based transplantation therapies.